Integer Holdings (Integer Holdings) ROCE % : 5.46% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Integer Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Integer Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was 5.46%.

Integer Holdings ROCE % Historical Data

The historical data trend for Integer Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integer Holdings ROCE % Chart

Integer Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.28

5.67

5.72

4.55

6.12

Integer Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															4.40	6.23	6.65	6.46	5.46

Integer Holdings ROCE % Calculation

Integer Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	161.926	/	( ( (2794.386 - 223.752)	+	(2942.653 - 220.969) )	/ 2 )
	=	161.926	/	( (2570.634	+	2721.684)	/ 2 )
	=	161.926	/	2646.159
	=	6.12 %

Integer Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	153.9	/	( ( (2942.653 - 220.969)	+	(3116.009 - 201.429) )	/ 2 )
	=	153.9	/	( ( 2721.684	+	2914.58 )	/ 2 )
	=	153.9	/	2818.132
	=	5.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Integer Holdings (NYSE:ITGR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Integer Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Integer Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Integer Holdings (Integer Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integer Holdings Corp (NYSE:ITGR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

WGB:Germany

Address

5830 Granite Parkway, Suite 1150, Plano, TX, USA, 75024

Website

https://www.integer.net

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.

Executives

Donald J Spence	director	C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Jean M. Hobby	director	10000 WEHRLE DRIVE, CLARENCE NY 14031
Jim Stephens	officer: President, CRM & Neuro	5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Diron Smith	officer: VP, Interim CFO	5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Joseph W Dziedzic	director	1801 BAYBERRY COURT, RICHMOND VA 23226
Pamela G Bailey	director	1200 G ST NW, STE 400, WASHINGTON DC 20005-3814
Jennifer M Bolt	officer: President, Electrochem	10000 WEHRLE DRIVE, CLARENCE NY 14031
Carter Houghton	officer: President, Electrochem	10000 WEHRLE DRIVE, CLARENCE NY 14031
Andrew Senn	officer: SVP, Strategy and Business Dev	5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Marshall Mcalister C Ii	officer: SVP, Gen Counsel & Secretary	1801 BAYBERRY COURT, P.O. BOX 18100, RICHMOND VA 23226
Margaret Carthy	officer: SVP, Quality & Regulatory Affa	5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024
Joseph F Flanagan	officer: EVP, Quality & Regulatory Affa	10000 WEHRLE DRIVE, CLARENCE NY 14031
Bill R Sanford	director	2617 BULRUSH LANE, NAPLES FL 34105
Anthony W Borowicz	officer: SVP Strategy,Corp Dev., IR	10000 WEHRLE DRIVE, CLARENCE NY 14031
Sheila Antrum	director	5830 GRANITE PARKWAY, SUITE 1150, PLANO TX 75024